Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Thomas D. Bethke"'
Publikováno v:
Chronobiology International. 27:1843-1853
The human circadian system is known to affect the pharmacokinetics and pharmacodynamics of several classes of respiratory disease medications. The current study involving 16 healthy adults investigated if the time-of-day of dosing of roflumilast, a n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3a738e9d7def3ff05cec687dbc18ec6
https://doi.org/10.3109/07420528.2010.520398
https://doi.org/10.3109/07420528.2010.520398
Autor:
Melanie Gleason, Kathleen A. Neville, Susan M. Abdel-Rahman, Stanley J. Szefler, Karl Zech, Gregory L. Kearns, Rolf Herzog, Thomas D. Bethke, Gezim Lahu
Publikováno v:
The Journal of Clinical Pharmacology. 48:978-985
Roflumilast is an orally administered phosphodiesterase 4 inhibitor that has potential for use in pediatric patients with asthma. The pharmacokinetics of roflumilast and roflumilast N-oxide were examined in adolescents and children with stable mild t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a74b558d0b2e526e6036c58c0142a89b
https://doi.org/10.1177/0091270008319466
https://doi.org/10.1177/0091270008319466
Publikováno v:
GMS German Medical Science; VOL: 13; DOC02 /20150127/
GMS German Medical Science, Vol 13, p Doc02 (2015)
GMS German Medical Science
GMS German Medical Science, Vol 13, p Doc02 (2015)
GMS German Medical Science
Objective: The objective of this project was to evaluate the quality and quantity of initial applications for a clinical trial according to § 7 of the German Good Clinical Practice (GCP) ordinance (German: GCP-Verordnung, GCP-V), the quality of eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31aa1f67558d6c2d3a0aea3e1e8aac63
http://nbn-resolving.de/urn:nbn:de:0183-0002064
http://nbn-resolving.de/urn:nbn:de:0183-0002064
Publikováno v:
Handbook of experimental pharmacology. (204)
Since more than two decades anti-inflammatory effects of inhibitors of phosphodiesterase-4 have been described in numerous cellular and animal studies and were finally confirmed in clinical trials. The path from an early, pioneering study with Ro20-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::996998a6cb4326eb43edbe7686b79251
https://pubmed.ncbi.nlm.nih.gov/21695636
https://pubmed.ncbi.nlm.nih.gov/21695636
Publikováno v:
Journal of clinical pharmacology. 52(2)
Numerous interactions are known for digoxin, which is a drug with a narrow therapeutic index and a substrate of P-glycoprotein (P-gp). This study investigated potential effects of coadministration on pharmacokinetics and safety of both drugs when a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe01f2d3501fc3da2f626235d4113ff
https://pubmed.ncbi.nlm.nih.gov/21257799
https://pubmed.ncbi.nlm.nih.gov/21257799
Publikováno v:
Phosphodiesterases as Drug Targets ISBN: 9783642179686
Since more than two decades anti-inflammatory effects of inhibitors of phosphodiesterase-4 have been described in numerous cellular and animal studies and were finally confirmed in clinical trials. The path from an early, pioneering study with Ro20-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::def89d9139b006319d3f32cacedad474
https://doi.org/10.1007/978-3-642-17969-3_3
https://doi.org/10.1007/978-3-642-17969-3_3
Publikováno v:
Arzneimittel-Forschung. 60(8)
A randomized, double-blind, 2-way crossover trial of 24 healthy volunteers investigated the influence of esomeprazole (CAS 119141-88-7) and pantoprazole (CAS 102625-70-7), both 1 x 40 mg orally for 11 days, on the pharmacokinetics and pharmacodynamic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca23c366a52b12820108754ab4eba3c6
https://pubmed.ncbi.nlm.nih.gov/20863004
https://pubmed.ncbi.nlm.nih.gov/20863004
Publikováno v:
Respiratory medicine. 105(2)
Summary Background The efficacy and safety profile of ciclesonide (CIC) in the treatment of asthma was evaluated in a large patient population in a real-life setting in Germany. Methods 24,037 patients with persistent mild/moderate bronchial asthma w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c235520b2dfc61720529b5a502dc4645
https://pubmed.ncbi.nlm.nih.gov/21067906
https://pubmed.ncbi.nlm.nih.gov/21067906
Publikováno v:
Clinical Drug Investigation. :1
Background and Objective: Osteoporosis is a progressive bone disorder. Its medical therapy typically involves calcium, vitamin D and antiresorptive drugs. The anabolic parathyroid hormones (PTHs) represent a major advance since they stimulate new bon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5928b2f6654d445c92449ba9a6c1f532
https://doi.org/10.2165/11538880-000000000-00000
https://doi.org/10.2165/11538880-000000000-00000